Orbis Medicines signs up to $1.4 billion partnership with Novo to develop macrocycle drugs for cardiometabolic disease

Orbis Medicines, which is backed by Eli Lilly, announced a new collaboration with Novo focused on drug discovery.

The agreement, valued at up to $1.4 billion, will target the creation of macrocycle molecules that blend characteristics of antibodies and small‑molecule drugs.

Both companies plan to apply this technology to cardiometabolic diseases, hoping the ring‑shaped compounds can address unmet therapeutic needs.

The deal gives Novo access to Orbis’s macrocycle platform while expanding Orbis’s pipeline and potential market impact in the cardiometabolic space.